Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H11N4O7P |
Molecular Weight | 330.1907 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OP(O)(=O)CNCC1=CC(=CC2=C1NC(=O)C(=O)N2)[N+]([O-])=O
InChI
InChIKey=ABFMMCZFKUIJGQ-UHFFFAOYSA-N
InChI=1S/C10H11N4O7P/c15-9-10(16)13-8-5(3-11-4-22(19,20)21)1-6(14(17)18)2-7(8)12-9/h1-2,11H,3-4H2,(H,12,15)(H,13,16)(H2,19,20,21)
Molecular Formula | C10H11N4O7P |
Molecular Weight | 330.1907 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: DOI: 10.1016/B0-08-045044-X/00171-1Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/26457482 | https://www.ncbi.nlm.nih.gov/pubmed/12113769 | https://www.pharmacodia.com/yaodu/html/v1/chemicals/adefdb0c97ab92a9e8d1437a75d6e27e.html
Sources: DOI: 10.1016/B0-08-045044-X/00171-1
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/26457482 | https://www.ncbi.nlm.nih.gov/pubmed/12113769 | https://www.pharmacodia.com/yaodu/html/v1/chemicals/adefdb0c97ab92a9e8d1437a75d6e27e.html
Becampanel (AMP397) is an aminomethylquinoxalinedione AMPA receptor antagonist. Also, AMP397 demonstrates binding to hydroxyapatite. AMP397 has no genotoxic potential in vivo. In particular, no genotoxic metabolite is formed in mammalian cells, and, if formed by intestinal bacteria, is unable to exert any genotoxic activity in the adjacent intestinal tissue. AMP397 has a significant oral bioavailability of 22% in mice and approximately 50% in humans. It was under development for the potential treatment of status epilepticus and other types of seizures. However, this research has been discontinued. It is also being evaluated for use in the treatment of neuropathic pain and cerebrovascular ischemia.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2096670 Sources: DOI: 10.1016/B0-08-045044-X/00171-1 |
11.0 nM [IC50] | ||
Target ID: CHEMBL2363055 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26457482 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: DOI: 10.1016/B0-08-045044-X/00171-1 https://www.ncbi.nlm.nih.gov/pubmed/17874969 |
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound. | 2002 Jul 25 |
|
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) antagonists: from bench to bedside. | 2010 Aug 12 |
|
Insights into the novel three 'D's of epilepsy treatment: drugs, delivery systems and devices. | 2010 Sep |
|
Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy. | 2014 Mar |
|
A General Strategy for Targeting Drugs to Bone. | 2015 Nov 23 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12113769
Rat: 60 mg/kg single dose
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12113769
Becampanel is one of the weakest nitroaromatic Salmonella typhimurium mutagens known. It induced 0.077 revertants/nmol, which lies at the lower end of the potency ranges found previously.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 22:05:11 UTC 2022
by
admin
on
Fri Dec 16 22:05:11 UTC 2022
|
Record UNII |
X3D0O800AJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47795
Created by
admin on Fri Dec 16 22:05:11 UTC 2022 , Edited by admin on Fri Dec 16 22:05:11 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
X3D0O800AJ
Created by
admin on Fri Dec 16 22:05:11 UTC 2022 , Edited by admin on Fri Dec 16 22:05:11 UTC 2022
|
PRIMARY | |||
|
C79860
Created by
admin on Fri Dec 16 22:05:11 UTC 2022 , Edited by admin on Fri Dec 16 22:05:11 UTC 2022
|
PRIMARY | |||
|
DTXSID50172241
Created by
admin on Fri Dec 16 22:05:11 UTC 2022 , Edited by admin on Fri Dec 16 22:05:11 UTC 2022
|
PRIMARY | |||
|
5491960
Created by
admin on Fri Dec 16 22:05:11 UTC 2022 , Edited by admin on Fri Dec 16 22:05:11 UTC 2022
|
PRIMARY | |||
|
Becampanel
Created by
admin on Fri Dec 16 22:05:11 UTC 2022 , Edited by admin on Fri Dec 16 22:05:11 UTC 2022
|
PRIMARY | |||
|
CHEMBL2107735
Created by
admin on Fri Dec 16 22:05:11 UTC 2022 , Edited by admin on Fri Dec 16 22:05:11 UTC 2022
|
PRIMARY | |||
|
188696-80-2
Created by
admin on Fri Dec 16 22:05:11 UTC 2022 , Edited by admin on Fri Dec 16 22:05:11 UTC 2022
|
PRIMARY | |||
|
8395
Created by
admin on Fri Dec 16 22:05:11 UTC 2022 , Edited by admin on Fri Dec 16 22:05:11 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |